Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases
Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases
复制标题
DOI：
10.1007/s10637-018-0670-1
复制
发表时间：
2018-12-01
影响因子：
3.4
通讯作者：
Koike, Kazuhiko
中科院分区：
文献类型：
--
作者：
Takahara, Naminatsu;Nakai, Yousuke;Koike, Kazuhiko
目的一线化疗（CT1）对胆道癌（BTC）的生存益处已得到证实，但二线化疗（CT2）的作用尚未完全阐明。方法回顾性分析2000年至2016年接受CT1治疗的连续性晚期BTC患者。我们研究了CT2的安全性和有效性，CT1后剩余生存的预后因素，并探讨了从CT2中获益的亚组。结果在294例接受CT1治疗的晚期BTC患者中，139例（47%）接受CT2治疗。CT2的有效率为4%，疾病控制率为52%，中位无进展生存期为2.8个月，总生存期为7.7个月。CT2与CT1后较长的剩余生存期相关（风险比[HR] 0.61，p
Purpose The survival benefit of first-line chemotherapy (CT1) for biliary tract cancer (BTC) is now established but the role of second-line chemotherapy (CT2) has not been fully elucidated yet. Methods Consecutive advanced BTC patients receiving CT1 between 2000 and 2016 were retrospectively studied. We investigated the safety and efficacy of CT2, prognostic factors for residual survival after CT1, and explored subgroups who would benefit from CT2. Results Among 294 patients receiving CT1 for advanced BTC, CT2 was given in 139 patients (47%). CT2 provided a response rate of 4%, a disease control rate of 52%, a median progression-free survival of 2.8 and overall survival of 7.7months, respectively. CT2 was associated with longer residual survival after CT1 (hazard ratio [HR] 0.61, p